Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia
- To promote harmonization between Cooperative Group Reference Laboratories conducting
minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.
OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative
Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are
analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease
studies by flow cytometry. Results are then provided to the National Cancer Institute for
assessment and comparability of test results.
Degree of concordance in the MRD assay results between laboratories
J. Milburn Jessup, MD
National Cancer Institute (NCI)
United States: Federal Government